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In the journal Toxins, a new section has been added to those already included, which will be
specifically devoted to uremic toxins. The term uremia refers to the gradual endogenous intoxication
that develops with the functional failure of the kidneys, which like the liver and the lungs, are tasked
with eliminating useless metabolic waste from the body. The name uremia is derived from the
highest concentrated and also first identified uremic retention solute: urea [1]. Kidney failure may
develop either in a short time span (Acute Kidney Injury—AKI) or more gradually (Chronic Kidney
Disease—CKD). Compounds that, in both conditions, accumulate in the body due to inadequate
renal clearance are called uremic retention solutes, and are designated as uremic toxins if they exert
a biological effect (toxicity) [2]. Both AKI and CKD affect a substantial proportion of the population
and are linked to important morbidity and mortality [3,4]. Since uremic toxins as well as the uremic
condition have been shown to affect most of the body functions, it is likely that uremic retention plays
a fundamental role in this morbidity and mortality [5].
The decision to add this new section on uremic toxins was largely influenced by the success of
two Special Issues on this topic that appeared in this same journal: one launched in November 2013
and edited by J Jankowski, and one launched in October 2016 and edited by myself.
Traditionally, the journal Toxins focuses on issues that are related to classical toxicology, which
essentially concentrates on exogenous compounds that enter the body from the external environment,
e.g., snake or spider venoms, food poisoning, or bacterial and environmental toxins. With uremic
toxicity, the journal moves to another area, the area of endogenously produced toxins, generated by
the metabolism of the body or by microbiota present in the body (essentially the intestinal microbiota).
Their toxicity is, to a large extent, related to their increased concentration in kidney failure as compared
to the normal situation, because of their decreased renal clearance, so that solutes which are normally
secreted by the healthy kidneys are retained in the body.
The research and literature on uremic toxicity have been booming in the recent years. Taking
indoxyl sulfate as an example, one of the relative newcomers to be recognized as a uremic toxin, this
compound was not once the topic of a publication in the years 1970 and 1980, only once in the year
1990 and four times in the year 2000, but 24 times in 2010 and 53 times in 2015. Uremic toxin research
has led to the identification of a number of newly detected toxins such as p-cresylsulfate [6], fibroblast
growth factor-23 (FGF-23) [7] and trimethylamine-N-oxide (TMAO) [8], but also to the rehabilitation
of the status of uremic toxin of solutes that previously had been considered inert and that now appear
to exert toxicity, such as urea [9] and symmetric dimethylarginine (SMDA) [10].
It is no surprise that with the extension of our knowledge on uremic toxins and their biological
functions, the number of publications on this issue has also grown. These include reports on newly
detected toxins and on a broad array of biological effects, especially those leading to cardio-vascular
damage, fibrosis and progression of kidney disease, which remain the main killers of the uremic
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population, but also on strategies to decrease the concentration of uremic toxins and their kinetics
during these processes. This can also include other aspects such as the pharmaceutical neutralization
of negative biological effects; the enhancement of renal and tubular removal of uremic toxins;
extracorporeal removal by adsorption or bio-artificial systems; and the modification of intestinal
generation and adsorption [11]. Rapidly developing novel methodological approaches such as those
related to metabolomics, proteomics, genomics and transcriptomics, as well as the endlessly growing
possibilities of molecular biology can be considered as powerful tools to extend this knowledge which,
by the application of biostatistics and innovative acquisitions such as systems biology, may lead to
novel therapeutics, and personalized medicine [12].
In addition to further exploration and extension of the knowledge on the effect and removal
of uremic toxins, we hope that this section will open avenues to at present insufficiently explored
areas of uremic toxicity, such as diet and uremic toxins; modifications of the intestinal milieu and
uremic toxin generation; other non-extracorporeal methods to reduce uremic toxin concentration or
their effects; uremic toxin retention in Acute Kidney Injury and after kidney transplantation; and
the effect of peritoneal dialysis on uremic toxin removal. Furthermore, there is an absolute need
for studies in quasi non-existing areas such as Randomized Controlled Trials exploring the effect of
decreasing the concentration of specific uremic toxins or groups of uremic toxins on hard outcomes,
more novel compact methods for extracorporeal removal allowing more flexibility and quality of
life to the uremic patient, and the role of “uremic toxins” in the population without kidney failure,
which, if such studies would turn out positive, would allow those molecules to be classified as general,
not only uremic, toxins.
Although, to date, such data could be submitted and still can be submitted to a broad array of
journals, it is a positive evolution that from now on a new alternative is offered allowing such articles
to be assembled as a group in a specific section of an easily accessible journal dedicated solely to
toxicity. We can only hope that our call is followed by a satisfactory number of relevant submissions.
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